Know Which Supplements Promoted for COVID-19 May Be Risky

More than 4 in 10 people have increased their use of supplements since the start of the COVID-19 pandemic.

Reinforce that there's still no evidence ANY supplement helps prevent or treat COVID-19.

Not all supplements are risky. But clarify which products to avoid.

Many patients swear by "immune boosters" such as colloidal tea...selenium...or vitamin C or D.

Tell patients to AVOID colloidal silver...due to risk of blue-gray skin discoloration, seizures, and liver or kidney toxicity.

Explain that drinking green tea seems safe. But caution about cases of liver toxicity with oral green tea EXTRACT.

If patients want to take vitamins or minerals, recommend usual daily doses...higher doses may do more harm than good.

Some supplements are touted for antiviral effects, such as elderberry...garlic...oleander...quercetin...or zinc.

Warn that oleander is POISONOUS. It contains oleandrin...a cardiac glycoside similar to digoxin that may cause fatal arrhythmias.

Be aware, there's not currently an oleander supplement...but it's a common flowering shrub. Educate not to consume any part.

Advise not to make elderberry syrup at home. The plant has a cyanide-producing chemical that can be toxic if not cooked properly.

Watch for interactions with may increase the risk of bleeding in patients taking an anticoagulant or antiplatelet.

If patients try zinc, suggest an oral form. Nasal zinc products are floating around online...but warn these may cause permanent loss of smell.

Supplements are often promoted for stress, anxiety, or sleep, such as ashwagandha...chamomile...kava...passion flower...or valerian.

Advise monitoring TSH if patients on a thyroid med start may stimulate thyroid hormone production.

Caution about reports of liver toxicity with kava.

Continue to ask about supplement use when updating med lists.

See our chart, COVID-19 Pharmacotherapy FAQs, to dispel myths. And rely on our Natural Medicines for advice about ANY supplement.

Key References

  • (9-21-20)
  • JAMA Dermatol 2015;151(6):667-8
  • J Family Med Prim Care 2020;9(1):136-40
  • Toxicol Rep 2020;7:386-402
Pharmacist's Letter. October 2020, No. 361003

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals